Advertisement
Screener

Perrigo Company plc (PRGO) Return on Tangible Equity

2.8 / 5 stars · 68/120 Roast Me

PERRIGO Co plc Return Tang Equity

Return on tangible equity is the profit a company earns on the physical and financial capital its shareholders own, leaving out goodwill and other intangible assets, shown as a percentage. It is net income divided by tangible equity, which is shareholder equity minus goodwill and intangibles; the table shows both amounts. Because acquired goodwill is removed, it runs higher than ROE for companies that grew by acquisition, and it has no meaning when goodwill exceeds equity. Goodwill and intangibles are taken at the latest reported date on or before each equity date. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • PERRIGO Co plc return tang equity for the quarter ending 2026-06-27 was 126.76%, a 2370.31% increase year-over-year.
  • PERRIGO Co plc return tang equity for the quarter ending 2026-03-28 was 124.30%, a 911.96% increase year-over-year.
  • PERRIGO Co plc return tang equity for the quarter ending 2025-12-31 was 97.22%, a 705.67% increase year-over-year.
  • PERRIGO Co plc return tang equity for the quarter ending 2025-09-27 was 3.94%, a 62.71% decline year-over-year.
  • PERRIGO Co plc return tang equity for fiscal 2025 was 97.22%, a 706.14% increase from fiscal 2024.
  • PERRIGO Co plc return tang equity for fiscal 2024 was 12.06%, a 1554.27% increase from fiscal 2023.
  • PERRIGO Co plc return tang equity for fiscal 2023 was 0.73%, a 90.26% decline from fiscal 2022.
  • PERRIGO Co plc return tang equity for fiscal 2022 was 7.48%, a change of 1118.78% from fiscal 2021.
Available history
2012-06-30 to 2026-06-27
Data captured

Historical Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2026-06-27126.76%-$1.73B-$1.37B
2026-03-28124.30%-$1.82B-$1.46B
2025-12-3197.22%-$1.43B-$1.47B
2025-09-273.94%-$51.8M-$1.31B
2025-06-285.13%-$80.3M-$1.56B
2025-03-2912.28%-$180.3M-$1.47B
2024-12-3112.07%-$171.9M-$1.42B
2024-09-2810.57%-$159.7M-$1.51B
2024-06-298.54%-$124.5M-$1.46B
2024-03-300.46%-$7.7M-$1.68B
2023-12-310.73%-$12.7M-$1.74B
2023-09-300.23%-$4.1M-$1.75B
2023-07-013.80%-$67.7M-$1.78B
2023-04-017.67%-$141.2M-$1.84B
2022-12-317.48%-$140.6M-$1.88B
2022-10-015.87%-$107.3M-$1.83B
2022-07-026.19%-$116.8M-$1.89B
2022-04-02-136.58%-$109.4M$80.1M
2021-12-31-1111.29%-$68.9M$6.2M
2021-10-02337.10%-$253.5M-$75.2M
2021-07-03-248.54%-$349.2M$140.5M
2021-04-03-165.64%-$230.9M$139.4M
2020-12-31-208.73%-$162.6M$77.9M
2020-09-260.72%-$6.6M-$914.4M
2020-06-27-24.67%$240.2M-$973.6M
2020-03-28-15.97%$188.6M-$1.18B
2019-12-31-66.35%$146.1M-$220.2M
2019-09-28-18.08%$246.5M-$1.36B
2019-06-29-9.82%$86.8M-$884.3M
2019-03-30-11.14%$114M-$1.02B
2018-12-31-11.18%$130.9M-$1.17B
2018-09-29-9.48%$122.7M-$1.29B
2018-06-30-17.97%$234.7M-$1.31B
2018-03-31-10.20%$128.9M-$1.26B
2017-12-31-9.24%$119.7M-$1.3B
2017-09-3090.05%-$1.31B-$1.46B
2017-07-01204.32%-$2.95B-$1.44B
2017-04-01252.80%-$3.41B-$1.35B
2016-12-31269.66%-$4.01B-$1.49B
2015-09-26-14.67%$373.5M-$2.55B
2015-06-276.46%$208.9M$3.24B
2015-03-28-87.77%$303.7M-$346M
2014-12-27-110.45%$374M-$338.6M
2014-09-27-15.65%$217.8M-$1.39B
2014-06-285.65%$232.9M$4.12B
2014-03-29-10.48%$191.9M-$1.83B
2013-12-28-13.39%$255.7M-$1.91B
2013-09-28-19.78%$447.7M-$2.26B

Annual Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2025-12-3197.22%-$1.43B-$1.47B
2024-12-3112.06%-$171.8M-$1.42B
2023-12-310.73%-$12.7M-$1.74B
2022-12-317.48%-$140.6M-$1.88B
2021-12-31-1111.29%-$68.9M$6.2M
2020-12-31-208.73%-$162.6M$77.9M
2019-12-31-66.35%$146.1M-$220.2M
2018-12-31-11.19%$131M-$1.17B
2017-12-31-9.23%$119.6M-$1.3B
2016-12-31269.66%-$4.01B-$1.49B
2015-06-274.21%$136.1M$3.24B
2014-06-285.65%$232.8M$4.12B
2013-06-29522.34%$441.9M$84.6M
2012-06-3037.42%$401.6M$1.07B

Similar stocks

Stock NameCountryMarket CapPE Ratio
NEKTAR THERAPEUTICS (NKTR)United States$2.026B-9.05
Generate Biomedicines, Inc. (GENB)United States$2.052B
UroGen Pharma Ltd. (URGN)$2.015B-18.42
Nuvation Bio Inc. (NUVB)United States$2.007B-13.12
Biohaven Ltd. (BHVN)United States$1.990B-3.83
Trevi Therapeutics, Inc. (TRVI)United States$2.091B-51.93
PALVELLA THERAPEUTICS, INC. (PVLA)United States$2.105B-35.55
Braveheart Bio, Inc. (BRVE)United States$2.106B
Bausch Health Companies Inc. (BHC)$2.113B-1.68
AGIOS PHARMACEUTICALS, INC. (AGIO)United States$1.962B-5.38